BACKGROUND: We reviewed the risk of second tumor (ST), both malignant and benign, in germinoma survivors followed at the Johns Hopkins Hospital (JHH). METHODS: Between 1977 and 2002, 27 patients with intracranial germinoma were treated with radiation therapy (RT). In the presence of competing events, a cumulative incidence function of ST was estimated using the minimal time interval from the date of diagnosis to the date of ST, date of death, or date of last follow-up. RESULTS: Five patients (18%) developed a ST of which 4 (15%) were malignant. One developed a benign falcine meningioma. The cumulative incidence of ST was 9% at 11 years (95% CI, 0-22%). CONCLUSIONS: The relative contributions of RT and patient susceptibility to a ST cannot be determined but suggests the need for long-term surveillance, including testicular self-exams in male germinoma survivors. Current trials of chemotherapy and reduced RT dose and volume offer the prospect of a lower risk of treatment-induced ST.
BACKGROUND: We reviewed the risk of second tumor (ST), both malignant and benign, in germinoma survivors followed at the Johns Hopkins Hospital (JHH). METHODS: Between 1977 and 2002, 27 patients with intracranial germinoma were treated with radiation therapy (RT). In the presence of competing events, a cumulative incidence function of ST was estimated using the minimal time interval from the date of diagnosis to the date of ST, date of death, or date of last follow-up. RESULTS: Five patients (18%) developed a ST of which 4 (15%) were malignant. One developed a benign falcine meningioma. The cumulative incidence of ST was 9% at 11 years (95% CI, 0-22%). CONCLUSIONS: The relative contributions of RT and patient susceptibility to a ST cannot be determined but suggests the need for long-term surveillance, including testicular self-exams in male germinoma survivors. Current trials of chemotherapy and reduced RT dose and volume offer the prospect of a lower risk of treatment-induced ST.
Authors: M C Baranzelli; C Patte; E Bouffet; D Couanet; J L Habrand; M Portas; O Lejars; P Lutz; E Le Gall; C Kalifa Journal: Cancer Date: 1997-11-01 Impact factor: 6.860
Authors: Amit Maity; Hui-Kuo G Shu; Alexander R Judkins; Michael J Fisher; Lisa E A Dwyer-Joyce; David J Vaughn Journal: J Neurooncol Date: 2004-10 Impact factor: 4.130
Authors: G J Bosl; E Dmitrovsky; V E Reuter; F Samaniego; E Rodriguez; N L Geller; R S Chaganti Journal: J Natl Cancer Inst Date: 1989-12-20 Impact factor: 13.506
Authors: E Brannon Morris; Amar Gajjar; James O Okuma; Yutaka Yasui; Dana Wallace; Larry E Kun; Thomas E Merchant; Maryam Fouladi; Alberto Broniscer; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2007-04-20 Impact factor: 44.544
Authors: J P Neglia; D L Friedman; Y Yasui; A C Mertens; S Hammond; M Stovall; S S Donaldson; A T Meadows; L L Robison Journal: J Natl Cancer Inst Date: 2001-04-18 Impact factor: 11.816
Authors: Brad J Greenfield; Sergio Jaramillo; Mirna Abboud; Anita Mahajan; Arnold C Paulino; Susan McGovern; Mary F McAleer; Murali Chintagumpala; M Fatih Okcu; Soumen Khatua; Jack Su; David R Grosshans Journal: Clin Transl Radiat Oncol Date: 2016-09-26
Authors: Rituraj Upadhyay; Divya Yadav; Bhanu P Venkatesulu; Raj Singh; Sujith Baliga; Raju R Raval; Margot A Lazow; Ralph Salloum; Maryam Fouladi; Elaine R Mardis; Nicholas G Zaorsky; Daniel M Trifiletti; Arnold C Paulino; Joshua D Palmer Journal: Front Oncol Date: 2022-08-12 Impact factor: 5.738